News

This week during Breast Cancer Awareness Month, we’re talking about metastatic breast cancer and Saint Luke’s Koontz Center—the region’s only center dedicated and designed specifically for these patients.

The study shows that the diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Semaglutide, the active ingredient on weight loss drugs Wegovy and Ozempic, shows evidence that the drug may also help reduce the risks of heart disease.

The diabetes and weight loss drug semaglutide significantly reduced symptoms and improved quality of life in people with obesity and the most common form of heart failure in a clinical trial.

Asian individuals with out-of-hospital cardiac arrest have similar rates of bystander cardiopulmonary resuscitation as White individuals, but have lower survival rates, according to a new study.

Dr. Mikhail Kosiborod presented on the benefits of a cardiometabolic center of excellence for patients with cardiometabolic diseases at the ADA conference in San Diego.

In a new analysis, researchers looked at how older patients in the ISCHEMIA trial responded to invasive strategy compared with more conservative management.

KCTV talked to one local colon cancer survivor and Dr. Robert Amajoyi about the importance of screenings and when to start.

Dr. Sanjaya Gupta, electrophysiologist at Saint Luke's Mid America Heart Institute, talks with KCTV about risk factors and new treatment available at Saint Luke's Atrial Fibrillation Clinic.

Rehospitalization after aortic valve replacement (AVR) is associated with an increased risk of patient mortality, according to new research.